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Background: The advent of high-throughput technologies to profile human tumors has generated unprecedented
insight into our molecular understanding of cancer. However, analysis of such high dimensional data is challenging
and requires significant expertise which is not routinely available to many cancer researchers.
Results: To overcome this limitation, we developed a freely accessible and user friendly Program to Identify
Molecular Signatures (PIMS). Importantly, such signatures allow important insight into cancer biology, as well as
provide clinical tools to identify potential biomarkers that might provide means to accurately stratify patients into
different risk or treatment groups. We evaluated the performance of PIMS by identifying and testing predictive
and prognostic gene signatures for breast cancer, using multiple breast tumor microarray cohorts representing
hundreds of patients. Importantly, PIMS identified signatures classified patients into high and low risk groups
with at least similar performance to other commonly used gene signature selection techniques.
Conclusions: Our program is contained entirely within a Microsoft Excel file and therefore requires no installation
of any additional programs or training. Hence, PIMS provides an accessible tool for cancer researchers to identify
predictive and prognostic gene signatures to advance their research.Background
Cancer oncologists are faced with the challenging task of
predicting which patients are most likely to benefit from
various treatment modalities, as well as avoid overtreating
patients who are unlikely to benefit from aggressive ther-
apy. For example, in breast cancer the traditional parame-
ters used by pathologists to determine patient prognosis
include age, tumor size, as well as various histopatho-
logical measurements such as clinical grade and hormone
receptor status [1,2]. More recently, the development of
gene expression profiling technologies such as microarrays
and quantitative RT-PCR have led to the use of molecular
signatures as additional means for providing prognostic
information for breast cancer patients [3-15]. Indeed, mul-
tigene predictors, which are also commonly called gene
signatures, are already being used clinically in some in-
stances, such as the MammaPrint® and OncotypeDX™
tests. Apart from breast cancer, gene signatures have also
been applied to other cancer types to determine patient* Correspondence: hassell@mcmaster.ca
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unless otherwise stated.prognosis and other clinical parameters of interest [16,17].
Additionally, examination of transcripts that comprise
gene signatures can reveal biological processes which
underlie clinical phenomena, and potentially uncover new
therapeutic avenues. Hence, gene signatures provide an
important tool to advance clinical as well as basic cancer
research. However, identifying predictive or prognostic
gene signatures requires the use of specialized software
and bioinformatics training, which ultimately hampers
their adoption where such infrastructure or skills are
lacking.
We hypothesized that an Excel program, which identi-
fied predictive and prognostic gene signatures and did
not require the installation or use of any other software
packages, would increase the accessibility of this type of
research. To this end, we adapted and improved an algo-
rithm we previously published [12] into a freely accessible
and user-friendly Excel program: Program to Identify
Molecular Signatures (PIMS). Here, we demonstrate its
use to identify prognostic gene signatures, which stratify
breast cancer patients into high and low risk groups, as
well as predictive gene signatures, which stratify breast
cancer patients into chemotherapy responsive and non-al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gram is robust and can be used to develop predictive and
prognostic gene signatures for user defined contexts.
Hence, we conclude that PIMS provides an accessible tool
for cancer researchers to identify predictive and prognos-
tic gene signatures to advance their research aims.
Methods
Microarray and clinical data
All data was obtained de-identified and obtained from
publically available sources through the gene expression
omnibus. We downloaded the following datasets as well
as associated clinical data from the gene expression omni-
bus (GSE2034 [n = 286] [11], GSE7390 [n = 198] [18],
GSE25055 [n = 310] [19], GSE25065 [n = 1] [19]), and
GSE14333(n = 290). All datasets were normalized using
RMA [20] using the public gene pattern server (http://
genepattern.broadinstitute.org).
Prognostic signatures
GSE7390 (n = 198) was used for training and GSE2034
(n = 286) was used for testing. Both GSE2034 and
GSE7390 comprise patients with node negative disease
who had received no treatment with endocrine agents or
chemotherapy. When possible we used distant metasta-
sis free survival at 10 years as the clinical endpoint for
this study. A summary of the clinical characteristics of
these cohorts are provide in Table 1. For the colon study,
GSE14333 was randomly divided into two equal sized
cohorts. One cohort was used as a training set, whereas
the other was used as a validation set.
Predictive signatures
GSE25055 was used as the training dataset and GSE25065
was used as the validation dataset. Both datasets comprise
patients treated with neoadjuvant chemotherapy compris-
ing an anthracycline and taxane. Patients with a post
chemotherapy residual cancer burden (RCB) of 0 or I were
considered to be responders, whereas those with an RCB
of II or III were considered to be non-responders. ATable 1 Summary of training and validation cohorts used
for prognostic signature
Characteristic Validation cohort Training cohort
GSE2034 GSE7390
Samples 286 198
Array type U133A U133A
ER positive 209 (73%) 134 (68%)
Median survival 86 months 144 months
Survival at 10 yrs 62% 69%
Total arrays: 484summary of the clinical characteristics of these cohorts
are provide in Table 2.
Feature selection algorithm
We significantly improved a previously published feature
selection algorithm [12] by adding leave-one-out cross-
validation as well as improved means of calculating sig-
nature scores, to produce software capable of identifying
prognostic/predictive gene signatures. Initially, gene ex-
pression for all patients is standardized across each
probe set, such that the mean and standard deviation of
each probe set is set to 0 and 1 respectively. Gene ex-
pression is then binned into the categories high, typical,
and low based on the 95% confidence interval of expres-
sion for a given gene. For example, high gene expression
indicates that the expression of a gene exceeds the 95%
confidence interval of expression for that gene among all
patients, and low expression indicates that the expres-
sion of a gene was less than the 95% confidence interval
of that gene among all patients. Genes with expression
within the 95% confidence interval of expression were
considered to have typical expression. A predictive score
(initially set at 0) for each probe set/gene is then calcu-
lated in the following way (Additional file 1: Figure S1):
1) Patients who had the event and have high
expression of a gene increase the predictive
score of that gene by 1.
2) Patients who had the event and have low
expression of a gene decrease the predictive
score of that gene by 1
3) Patients who did not have the event and have
high expression of a gene decrease the predictive
score of that gene by 1.
4) Patients who did not have the event and have
low expression of a gene increase the predictive
score of that gene by 1.
5) Typical expression of a gene in any patient
does not change its predictive score.
In this fashion, high absolute predictive gene scores
may be achieved by either high or low expression of a
given gene being related to patient outcome. Finally, weTable 2 Summary of training and validation cohorts used
for predictive signature
Characteristic Discovery cohort Validation cohort
GSE25055 GSE25065
Samples 310 198
Array type U133A U133A
ER positive 174 (56%) 123 (62%)
RCB0/I vs RCBII/III 86 (29%) 32 (27%)
Total arrays: 508
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predictive genes. The magnitude of the difference in
mean gene expression between the high and low risk
groups is used as a tie-breaker. In this fashion, the ex-
pression of probe sets that receive the highest scores are
associated with high risk tumors (those that reccur
within 10 years), and the expression of probe sets that
receive the lowest scores are associated with low risk tu-
mors (those that do not reccur within 10 years). In order
to estimate the performance of a given signature in an
unbiased fashion, and reduce over-fitting, we added cap-
acity for PIMS to perform leave one-out-cross validation.
Screenshots of this process as well as detailed instructions
can be found in Additional file 2 (PIMS user guide).
To assign signature scores to patients, the expression
values for each gene were transformed such that the
mean and standard deviation were set to 0 and 1 in each
dataset, respectively. A signature score was calculated










Where x is the transformed expression, n is the num-
ber of probe sets, P is the set of probes with reported
positive correlation to the target probe set, and N is the
set of probes with reported negative correlation to the
target probe set [13,15].
Software
The program is contained entirely within an Excel file,
therefore requiring no installation. All that is required to
operate our program is Excel 2007 or later. Additionally,
our program is freely accessible and is included as a
supplementary file, which accompanies this manuscript.
The code for our program is written in Visual Basic for
Applications and is easily accessible from within Excel.
Prediction Analysis of Microarrays (PAM)
PAM was installed and used in R according to the avail-
able manual [21].
Binary Regression (BR)
The binary regression software was a generous gift from
the West lab (http://www.stat.duke.edu/~mw/), and was
used as a MATLAB plug-in [22].
Performance assessment
For the prognostic validation, we calculated the hazard
ratio (HR), logrank p-value (median cut-point), area under
the ROC curve (AUC), and specificity at 80% sensitivity,
to determine the significance of the difference in survival
between predicted good and poor survival groups. For the
predictive validation, we calculated the odds ratio (OR)and Fisher’s exact test to assess performance. Survival
analysis and all associated statistical tests were performed
using IBM SPSS Statistics and R.
Results
Identification of a prognostic gene signature
We sought to develop user-friendly and accessible soft-
ware that could reliably identify predictive and prognostic
gene signatures, which we tested by identifying and testing
predictive and prognostic gene signatures from global
gene expression profiles of breast tumors. In short, PIMS
computes a predictive score for each gene, such that genes
which receive the highest absolute predictive scores are
tightly linked to poor or good outcome. Based on the pre-
dictive scores, it is possible to select an n-feature gene sig-
nature, which comprises n-genes that received predictive
scores of the greatest magnitude. The expression of genes
comprising a signature can then be evaluated in a given
patient, resulting in that patient receiving a signature
score. Gene signatures can then be validated by testing
whether or not the signatures scores are associated with
the clinical feature of interest. In this case, we used pa-
tients who were or were not distant metastasis free within
10 years after diagnosis as phenotypic classes, and used
our software to identify prognostic genes that stratify
patients into these classes (Figure 1A, Additional file 1:
Figure S1). Because it is difficult to know, a priori, the
optimal number of n-features (in this case features are
Affymetrix probesets/genes) to include in a gene signature,
we introduced leave-one-out cross-validation (LOOCV) as
a means to identify an optimal number of features to in-
clude. To this end, PIMS produced scores that predicted
the outcome of each patient using LOOCV. To determine
the optimal number of genes to include in our signature,
we identified 50 signatures of length n = 1,2,3,…,50 and
compared the p-values from Cox regression of the survival
on predicted scores for each patient for each n-length sig-
nature (Figure 1B). We found that a signature comprising
12 genes yielded the lowest p-value (p < 0.0001, Figure 1B),
suggesting that the expression of 12 genes optimally strat-
ify patients into good and poor prognosis groups. Indeed,
we found that a 12 gene signature selected and evaluated
by PIMS (LOOCV) could stratify patients into high and
low risk groups with highly statistically significant differ-
ences in survival (p < 0.00000001, Figure 1C and D). Taken
together, these data suggest that PIMS provides a simple
and robust means of identifying prognostic gene signa-
tures in cancer patients.
Pathway analysis of the prognostic genes selected by
PIMS demonstrated that these genes were enriched in
several biological processes previously linked to breast
cancer patient outcome (Additional file 3: Table S1). These
included regulation of adherens junctions as well as
nuclear regulation of SMAD2/3 signaling, which occurs
Figure 1 Identification of prognostic gene signatures using PIMS. A) Summary of PIMS algorithm. B) Cox regression p-values compared to
n-length signatures selected by PIMS (n = 12 genes, p < 0.0001). C) Survival analysis of patients stratified into high and low risk groups by the PIMS
12-gene signature (HR:4.1, p = 0.000007). D) Heatmap and individual patient signature scores for 12-gene signature.
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ported linkage between adherens junction, TGFβ signaling
and breast patient prognosis, these results confirm the
capacity of PIMS to select prognostic genes.
Comparison with other models
To compare the predictive accuracy of PIMS identified
signatures with those identified by other commonly used
software packages, we compared the PIMS 12-gene sig-
nature (described above) with similar 12 gene signatures
identified using either binary regression or Predictive
Analysis of Microarrays (PAM). In each case, we used
GSE7390 as the discovery dataset and GSE2034 as a val-
idation dataset. To compare the various means for signa-
ture selection we calculated the hazard ratio (HR) and
logrank p-value (median cut-point), area under the ROC
curve (AUC) for survival at 10 years, as well as test
specificity at 80% sensitivity. We found that both binary
regression and PAM identified signatures which were
highly prognostic in the discovery dataset (Figure 2A and B,
Table 3). Based on our evaluation criteria we found
that each feature selection method identified signatures
that were significantly associated with outcome (Table 3,
GSE7390 row).Because independent validation of a gene signature is
a more accurate measurement of its actual prognostic
capacity, we sought to evaluate PIMS, binary regression
and PAM selected signatures on an independent cohort
of breast cancer patients (GSE2034). GS2034 is a cohort
of 286 chemotherapy naïve, node-negative breast cancer
patients, thus having characteristics similar to those used
for the training data set. Analysis of this data revealed
that the PIMS selected signature performed nominally
better than either the PAM or binary regression selected
signatures, albeit marginally so (Table 1: winners bolded). In
the validation tests, PIMS, PAM and binary regression se-
lected signatures produced hazard ratios of 2.0 (p = 0.0003),
2.0 (p = 0.0004), and 1.4 (p = 0.06), respectively. AUC ana-
lysis, Cox regression, and sensitivity and specificity com-
parisons all suggested that each feature selection method
identified a signature that was also associated with patient
outcome in the validation cohort (Figure 3). Notably, the
PIMS selected signature was the nominal winner of each
category. We also observed that each signature had poorer
performance during independent validation, suggesting
that each signature suffered from over-fitting during train-
ing, a phenomena which is common to signatures identi-
fied from high dimensional data. Nonetheless, our PIMS
Figure 2 PAM and binary regression identify prognostic gene signatures. A) Survival analysis of patients stratified into high and low risk
groups by a 12 gene signature identified using binary regression (HR: 4.4, p = 0.00003). B) Survival analysis of patients stratified into high and low
risk groups by a 12 gene signature identified using PAM (HR: 9.1 p < 0.000001).
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to signatures selected with other commonly used feature
selection algorithms.
Comparison of PIMS with randomly generated signatures
Recently, many groups have found that randomly gener-
ated gene signatures significantly correlate with outcome
using standard tests, such as the ones we used as described
[23,24]. To confirm that PIMS identified signatures that
performed better that those selected by random means, we
generated 10,000 random 12 gene signatures and used Cox
regression to test their association with patient outcome
(GSE2034, validation set). In support of these studies, we
found that 20% of the randomly generated signatures wereTable 3 Comparison of PIMS, PAM, and binary regression identified prognostic signatures
GSE7390 (Discovery) GSE2034 (Validation
PIMS Hazard ratio 7.6 2
p-value Log-rank Test <0.0001 0.0003
AUC 0.81 0.65
AUC p-value <0.0001 <0.0001
Specificity at 80% sensitivity 0.74 0.37
Cox regression p-value <0.0001 0.0002
PAM Hazard ratio 9.3 2
p-value Log-rank Test <0.0001 0.0004
AUC 0.82 0.62
AUC p-value <0.0001 0.001
Specificity at 80% sensitivity 0.69 0.31
Cox regression p-value <0.0001 0.0002
Binary regression Hazard ratio 4.4 1.4
p-value Log-rank Test <0.0001 0.063
AUC 0.77 0.57
AUC p-value <0.0001 0.04
Specificity at 80% sensitivity 0.56 0.32
Cox regression p-value <0.0001 0.01significantly associated with outcome. However, we also
found that the PIMS identified signature performance
placed it within the 99th percentile of randomly generated
signatures (Figure 4A, blue arrow). Hence, we concluded
that PIMS selects gene signatures with robust prognostic
capacity, and PIMS selected signatures are not simply
prognostic by chance.
Identification of a predictive gene signature
Our previous data suggested that PIMS could be used to
identify robust prognostic gene signatures. Because iden-
tifying predictive gene signatures is also of significant
interest to cancer researchers, we tested whether PIMS
could identify gene signatures predictive of therapy)
Figure 3 Survival analysis of PIMS PAM and binary regression identified signatures on a independent cohort. A) Survival analysis of
patients stratified into high and low risk groups by a 12 gene signature identified using PIMS (HR: 2.0, p = 0.0030). B) Survival analysis of patients
stratified into high and low risk groups by a 12 gene signature identified using binary regression (HR: 1.4, p = 0.063). C) Survival analysis of
patients stratified into high and low risk groups by a 12 gene signature identified using PAM (HR: 2.0 p = 0.0036).
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that could predict breast cancer tumor response to pre-
operative or neoadjuvant chemotherapy. For this aim,
we used GSE25055 (n = 310) and GSE25065 (n = 198) as
training and validation cohorts, respectively. Each cohort
comprises patients that were treated with neoadjuvant
anthracycline and taxane chemotherapy, and were eva-
luated for residual cancer burden (RCB) post-therapy. In
this case, we considered patients with RCB0/I post
therapy as responders or chemotherapy sensitive, and
those with RCBII/III as non-responders, or chemotherapy
resistant [25]. To identify an optimal signature we used
PIMS to identify and LOOCV to test n-length signatures
(n = 1,2,3,....,200), and measured the AUC using ROC
analysis of each n-length signature. We identified 82
probesets as the optimum signature size with an AUC at
0.73 (Figure 5A). Moreover, PIMS LOOCV could stratify
patients (median cut-point) into chemotherapy sensi-
tive and chemotherapy resistant patient groups (OR: 4.0,
p < 0.0001, Figure 5B, C). To confirm that the PIMS iden-
tified signature was robustly predictive, we also tested the
capacity of the 82 gene signature to identify responders in
the additional validation dataset. The 82 gene signatureFigure 4 PIMS signature outperforms randomly generated signatures
signatures. Cox-regression p-value for the PIMS signature is shown by blue arcould accurately segregate the patients from the validation
cohort into responders and non-responders (AUC= 0.70,
OR: 4.4, *p = 0.002, Figure 5D and E). We also compared
the accuracy of the PIMS identified signature to that of
similar signatures derived using either PAM or binary re-
gression (Table 4). In this comparison, which included
ROC curve analysis and contingency analysis, we found
that the PIMS, PAM, and binary regression identified pre-
dictive signatures were directly comparable in terms pre-
dictive accuracy.
Hence, these data suggest that PIMS identified signa-
tures have the capacity to identify predictive gene signa-
tures. Taken with our previous data, we conclude that
PIMS provides a robust means of identifying predictive
and prognostic gene signatures in breast cancer.
PIMS identifies prognostic gene signatures in additional
tumor types
To confirm that the utility of PIMS was not limited to
breast cancers, we tested its capacity to identify prognostic
signatures for risk stratification of colon cancer patients.
Briefly, we obtained publically available gene expression
profiling data for which clinical follow-up data was also. A) Comparison of the PIMS signature with 10,000 randomly generated
row (p = 0.00020, rank: 89/10,000).
Figure 5 Identification of a predictive gene signature using PIMS. A) The optimal signature length was identified by using ROC analysis for
each n-length signature (n = 1-200, n = 82). B) ROC analysis of 82 gene signature evaluated using LOOCV (AUC: 0.73, p < 0.000001). C) LOOCV of
the 82 gene signature stratified patients into responder and non-responder groups (OR: 4.0, p < 0.00001). D) ROC analysis of 82 gene signature in
validation cohort (AUC: 0.70, p = 0.0012). E) 82 gene signature stratified validation cohort patients into responder and non-responder groups
(OR: 4.4, p = 0.002).
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into equally sized training and validation cohorts, and
implemented PIMS to identify a 12 feature signature that
robustly stratified training patients into good and poor
outcome groups. Application of this 12 gene signature to
the validation cohort demonstrated striking stratificationTable 4 Comparison of PIMS, PAM, and binary regression
identified predictive signatures
Test GSE25065 (Validation cohort)
PIMS AUC 0.70, p = 0.001
Odds ratio 4.4
Fisher’s exact test p = 0.002
PAM AUC 0.72, p = 0.0002
Odds ratio 4.4
Fisher’s exact test p = 0.002
Binary regression AUC 0.71, p = 0.0004
Odds ratio 4.4
Fisher’s exact test p = 0.002of these patients into high and low risk groups (Additional
file 4: Figure S2, HR: 1.3, *p = 0.0004, log-rank test). Taken
together, these data demonstrate the capacity for PIMS to
identify prognostic signatures in colon cancers. Overall,
we conclude that PIMS provides a robust and reprodu-
cible method to identify prognostic and predictive gene
signatures.
Discussion
Here, we report a freely accessible and user friendly
program to identify predictive and prognostic gene
signatures. An important characteristic of our program is
that it is all contained within a single Microsoft Excel file.
Excel is highly used and widely available: therefore the
implementation of our program is very straightforward.
By contrast, the vast majority of current feature selec-
tion techniques require the use of various clustering
and classification algorithms that require installation
of advanced statistical software packages as well as a
significant time investment for training with the same
software.
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suggested that PIMS identified signatures that performed
with comparable accuracy to other commonly used fea-
ture selection techniques. It is noteworthy that for each
signature, regardless of their method of derivation, the
predictive accuracy diminished between the training and
validation groups, suggesting that over-fit occurred during
training. This is a common property of feature selection
algorithms [10,26]. To confirm that PIMS selected signa-
tures were robustly associated with the defined clinical
variables, we also generated 10,000 randomly selected
signatures and compared their predictive capacity with
the PIMS selected signature. In this case, the performance
of the PIMS signature was within the 99th percentile of
the randomly generated signatures, thereby validating
the robustness of PIMS selected signatures.
Whereas the experiments presented here focused on
identifying prognostic and predictive gene signatures for
breast cancer from microarray data, PIMS would also be
appropriate to identify similar such signatures for differ-
ent cancer types (lung, ovarian, colon…etc). Indeed, this
notion is supported by our demonstration that PIMS
can similarly identify prognostic gene signatures in colon
cancer patients. Moreover, PIMS would readily function
on other data formats as well, such as RNAseq data, or
even copy number array data. Accordingly, we suggest
that PIMS is broadly applicable to most commonly used
high-throughput techniques used to profile tumors.Conclusions
We have built upon our previously published feature
selection algorithm and packaged it into a freely access-
ible, user-friendly Excel file. Our data suggest that PIMS
identifies gene signatures that are robustly associated with
user defined clinical variables. Hence, PIMS represents a
broadly applicable method to generate prognostic and
predictive gene signatures that we expect will be highly
useful to the research community.Additional files
Additional file 1: Figure S1. The expression of each gene is
standardized across the cohort of patients. The scoring of the gene is
relative to the 95% confidence interval (A). Using the resulting expression
value for each gene and the phenotype data we can calculate a
predictive score for each gene. Table B illustrates how each combination
affects the predictive score of each gene. Finally leave-one-out cross-
validation (C) is used to find the best sized signature.
Additional file 2: PIMS tutorial.
Additional file 3: Pathway analysis of prognostic PIMS signature.
Additional file 4: Figure S2. PIMS identifies prognostic signatures in
colon cancer (HR: 1.3, *p=0.0004, log-rank test) *test).
Competing interests
The authors declare that they no competing interests.Authors’ contributions
Conception of project RMH. Study design RMH & SDC. Completion of
research SDC & RMH. Statistical analysis, SDC & RMH. Interpretation of data
and writing of manuscript RMH, SDC & JAH. All authors read and approved
the final manuscript.
Acknowledgements
The authors wish to acknowledge funding from the Canadian Breast Cancer
Foundation and the Canadian Stem Cell Network that supported the
research described herein. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Received: 9 June 2014 Accepted: 24 July 2014
Published: 18 August 2014
References
1. Hayes DF, Trock B, Harris AL: Assessing the clinical impact of prognostic
factors: when is ‘statistically significant’ clinically useful? Breast Cancer Res
Treat 1998, 52:305–319.
2. American Society for Clinical Oncology: 1997 update of recommendations
for the use of tumor markers in breast and colorectal cancer. Adopted
on November 7, 1997 by the American Society of Clinical Oncology.
J Clin Oncol 1998, 16:793–795.
3. Kim C, Paik S: Gene-expression-based prognostic assays for breast cancer.
Nat Rev Clin Oncol 2010, 7:340–347.
4. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner F, Walker M,
Watson D, Park T, Hiller W, Fisher E, Wickerham D, Bryant J, Wolmark N:
A multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med 2004, 351:2817–2826.
5. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He
YD, van’t Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ:
Robustness, scalability, and integration of a wound-response gene
expression signature in predicting breast cancer survival. Proc Natl Acad
Sci U S A 2005, 102:3738–3743.
6. Van de Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D,
Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S,
Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a
predictor of survival in breast cancer. N Engl J Med 2002, 347:1999–2009.
7. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL,
van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM,
Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling
predicts clinical outcome of breast cancer. Nature 2002, 415:530–536.
8. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P,
Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H,
Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M:
Gene expression profiling in breast cancer: understanding the molecular
basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006,
98:262–272.
9. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer.
N Engl J Med 2009, 360:790–800.
10. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G: A comparative
study of survival models for breast cancer prognostication based on
microarray data: does a single gene beat them all? Bioinformatics 2008,
24:2200–2208.
11. Wang Y, Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F,
Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T,
Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict
distant metastasis of lymph-node-negative primary breast cancer.
Lancet 2005, 365:671–679.
12. Hallett RM, Dvorkin A, Gabardo CM, Hassell JA: An algorithm to discover
gene signatures with predictive potential.J Exp Clin Cancer Res 2010,
29:120.
13. Hallett RM, Dvorkin-Gheva A, Anita B, Hassell JA: A gene signature for
predicting outcome in patients with basal-like breast cancer.
Sci Reports 2012, 2:227.
14. Hallett RM, Hassell JA: E2F1 and KIAA0191 expression predicts breast
cancer patient survival. BMC Res Notes 2011, 4:95–95.
15. Hallett RM, Pond G, Hassell JA: A target based approach identifies
genomic predictors of breast cancer patient response to chemotherapy.
BMC Med Genomics 2012, 5:16.
Chorlton et al. BMC Research Notes 2014, 7:546 Page 9 of 9
http://www.biomedcentral.com/1756-0500/7/54616. Subramanian J, Simon R: Gene expression–based prognostic signatures in
lung cancer: ready for clinical use? J Natl Cancer Inst 2010, 102:464–474.
17. Wouters BJ, Löwenberg B, Delwel R: A decade of genome-wide gene
expression profiling in acute myeloid leukemia: flashback and prospects.
Blood 2009, 113:291–298.
18. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B,
Viale G, Delorenzi M, Zhang Y, Assignies MS, Bergh J, Lidereau R, Ellis P,
Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C:
Strong time dependence of the 76-gene prognostic signature for
node-negative breast cancer patients in the TRANSBIG multicenter
independent validation series. Clin Cancer Res 2007, 13:3207–3214.
19. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T,
Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R,
Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N,
Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A,
O’Shaughnessy J, Hortobagyi GN, Symmans WF: A genomic predictor of
response and survival following taxane-anthracycline chemotherapy for
invasive breast cancer. JAMA 2011, 305:1873–1881.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U,
Speed TP: Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 2003, 4:249–264.
21. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer
types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A
2002, 99:6567–6572.
22. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H,
Olson JA, Marks JR, Nevins JR: Predicting the clinical status of human
breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A
2001, 98:11462–11467.
23. Venet D, Dumont JE, Detours V: Most random gene expression signatures
are significantly associated with breast cancer outcome. Plos Comput Biol
2011, 7:e1002240–e1002240.
24. Starmans MHW, Fung G, Steck H, Wouters BG, Lambin P: A simple but
highly effective approach to evaluate the prognostic performance of
gene expression signatures. Plos One 2011, 6:e28320.
25. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V,
Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE,
Hortobagyi GN, Pusztai L: Measurement of residual breast cancer burden
to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007,
25:4414–4422.
26. Koscielny S: Why most gene expression signatures of tumors have not
been useful in the clinic. Sci Transl Med 2010, 2:14ps2–14ps2.
doi:10.1186/1756-0500-7-546
Cite this article as: Chorlton et al.: A program to identify prognostic and
predictive gene signatures. BMC Research Notes 2014 7:546.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
